NEOS Neos Therapeutics Inc.

0.77
-0.01  -1%
Previous Close 0.78
Open 0.8
Price To Book -6.44
Market Cap 38,456,408
Shares 49,743,122
Volume 101,061
Short Ratio
Av. Daily Volume 264,431
Stock charts supplied by TradingView

NewsSee all news

  1. Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results

    – Full year 2019 net revenues increased by 29% and operating loss decreased by $33M – – Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end – – NT0502 Phase 1 ascending dose trial

  2. Neos Therapeutics to Host Fourth Quarter and Year-End 2019 Financial and Operating Results Conference Call on March 13th, 2020

    DALLAS and FORT WORTH, Texas, March 06, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products,

  3. Neos Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference

    DALLAS and FORT WORTH, Texas, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products,

  4. Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea

    DALLAS and FORT WORTH, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products,

  5. Neos Therapeutics Reports Third Quarter 2019 Financial Results

    DALLAS and FORT WORTH, Texas, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced September 15, 2017.
NT-0201
Attention deficit hyperactivity disorder (ADHD)
Approved January 27, 2016.
Adzenys XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Approval announced June 19, 2017.
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Phase 1 ascending dose trial initiation planned in 2H 2020.
NT0502
Sialorrhea

Latest News

  1. Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results

    – Full year 2019 net revenues increased by 29% and operating loss decreased by $33M – – Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end – – NT0502 Phase 1 ascending dose trial

  2. Neos Therapeutics to Host Fourth Quarter and Year-End 2019 Financial and Operating Results Conference Call on March 13th, 2020

    DALLAS and FORT WORTH, Texas, March 06, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products,

  3. Neos Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference

    DALLAS and FORT WORTH, Texas, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products,

  4. Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea

    DALLAS and FORT WORTH, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products,

  5. Neos Therapeutics Reports Third Quarter 2019 Financial Results

    DALLAS and FORT WORTH, Texas, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

  6. Neos Therapeutics to Host Third Quarter 2019 Financial and Operating Results Conference Call on November 8, 2019

    DALLAS and FORT WORTH, Texas, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

  7. Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

    DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

  8. Neos Therapeutics to Present at Two Upcoming September Conferences

    DALLAS and FORT WORTH, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and